{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:45:20Z","timestamp":1773873920404,"version":"3.50.1"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>By increasing the activity of the immune system, immune checkpoint inhibitors (ICPI) can have adverse inflammatory effects, which are referred to as immune-related adverse effects (irAEs). In this review, we present the recommendations for the appropriate identification and treatment of irAEs associated with ICPI to increase the safety and effectiveness of therapy with these immuno-oncological drugs. Several guidelines to manage irAEs adopted by different American and European societies in the field of oncology were identified. A narrative review of the several strategies adopted to manage irAEs was performed. With close clinical surveillance, ICPI can be used even in patients who have mild irAEs. Moderate to severe events require early detection and appropriate treatment, particularly in patients with a history of transplantation or pre-existing autoimmune disease. In most cases, adverse reactions can be treated with the interruption of treatment and\/or supportive therapy, which includes, in serious adverse reactions, the administration of immunosuppressants. The identification and treatment of irAEs in the early stages may allow patients to resume therapy with ICPI. This review is an instrument to support healthcare professionals involved in the treatment and monitoring of patients who are administered ICPI, contributing to the timely identification and management of irAEs.<\/jats:p>","DOI":"10.3390\/vaccines8040575","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T09:04:12Z","timestamp":1601543052000},"page":"575","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Management of the Adverse Effects of Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2112-2835","authenticated-orcid":false,"given":"Manuel","family":"Morgado","sequence":"first","affiliation":[{"name":"Pharmaceutical Services of University Hospital Center of Cova da Beira, 6200-251 Covilh\u00e3, Portugal"},{"name":"Research Unit for Inland Development, Polytechnic of Guarda (UDI-IPG), 6300-559 Guarda, Portugal"},{"name":"Health Sciences Research Centre, University of Beira Interior (CICS-UBI), 6200-506 Covilh\u00e3, Portugal"},{"name":"Health Sciences Faculty, University of Beira Interior (FCS-UBI), 6200-506 Covilh\u00e3, Portugal"}]},{"given":"Ana","family":"Pl\u00e1cido","sequence":"additional","affiliation":[{"name":"Research Unit for Inland Development, Polytechnic of Guarda (UDI-IPG), 6300-559 Guarda, Portugal"}]},{"given":"Sandra","family":"Morgado","sequence":"additional","affiliation":[{"name":"Pharmaceutical Services of University Hospital Center of Cova da Beira, 6200-251 Covilh\u00e3, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0169-3788","authenticated-orcid":false,"given":"F\u00e1tima","family":"Roque","sequence":"additional","affiliation":[{"name":"Research Unit for Inland Development, Polytechnic of Guarda (UDI-IPG), 6300-559 Guarda, Portugal"},{"name":"Health Sciences Research Centre, University of Beira Interior (CICS-UBI), 6200-506 Covilh\u00e3, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia-Pacific J. Oncol. Nurs."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","unstructured":"(2020, September 08). The Immune Checkpoint Inhibitors Unleashed to Fight Cancer. Available online: https:\/\/www.the-rheumatologist.org\/article\/immune-checkpoint-inhibitors-unleashed-fight-cancer\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev-pathmechdis-012418-012818","article-title":"Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology","volume":"14","author":"Ogino","year":"2018","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/path.5236","article-title":"Integration of microbiology, molecular pathology, and epidemiology: A new paradigm to explore the pathogenesis of microbiome-driven neoplasms","volume":"247","author":"Hamada","year":"2019","journal-title":"J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","author":"Kanz","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","unstructured":"DBuffery, D.B., Lorton, L.J., and Guglielmon, C. (2018). Managing immune checkpoint inhibitor side effects: Key recommendations. Oncology Practice Management, Engage Healthcare Communications, Engage Healthcare Communications, LLC."},{"key":"ref_12","unstructured":"(1947). The National Cancer Institute. Can. Med. Assoc. J., 56, 558."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2018","journal-title":"Endocr.-Related Cancer"},{"key":"ref_14","unstructured":"MacDougall, A.K. (2018). The Pharmacist\u2019s Role in Educating the Health-Care Team about Adverse Effects of Immune Checkpoint Inhibitors, The ASCO Post."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CJI.0000000000000194","article-title":"Management of immune-mediated cytopenias in the era of cancer immunotherapy","volume":"41","author":"Sun","year":"2018","journal-title":"J. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2017","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Brand","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/CAD.0000000000000661","article-title":"A case of severe Pembrolizumab-induced neutropenia","volume":"29","author":"Ariane","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res."},{"key":"ref_26","first-page":"9602540","article-title":"Immune toxicity with checkpoint inhibition for metastatic melanoma: Case series and clinical management","volume":"2018","author":"Lomax","year":"2018","journal-title":"J. Ski. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2169\/internalmedicine.9851-17","article-title":"Nivolumab induces sustained liver injury in a patient with malignant melanoma","volume":"57","author":"Matsubara","year":"2018","journal-title":"Intern. Med."},{"key":"ref_29","first-page":"879","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma","volume":"41","author":"Huffman","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.12659\/AJCR.908570","article-title":"Resolution of infliximab-refractory nivolumab-induced acute severe enterocolitis after cyclosporine treatment in a patient with non-small cell lung cancer","volume":"19","author":"Iyoda","year":"2018","journal-title":"Am. J. Case Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4292\/wjgpt.v10.i1.29","article-title":"Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report","volume":"10","author":"Nassri","year":"2019","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: A case report","volume":"67","author":"Kashima","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/575\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:15:41Z","timestamp":1760177741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040575"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040575","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}